Real-World Effectiveness of Targeted-Release Budesonide in IgA Nephropathy with Near-Universal SGLT2 Inhibitor Use.
4 affiliations
- 1Renal Department, Northern Care Alliance NHS Foundation Trust, Salford, UK.
- 2Division of Cardiovascular Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
- 3Renal Department, Northern Care Alliance NHS Foundation Trust, Salford, UK, [email protected].
- 4Division of Cardiovascular Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK, [email protected].
Abstract
Introduction
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of end-stage kidney disease. Targeted-release formulation (TRF) budesonide demonstrated significant reductions in proteinuria and attenuation of estimated glomerular filtration rate (eGFR) decline in the randomised NefIgArd trial. However, real-world effectiveness and tolerability in routine clinical practice remain less well characterised. We report real-world outcomes following initiation of TRF budesonide in a tertiary renal centre.Methods
We conducted a retrospective cohort study of all patients with biopsy-proven IgAN initiated on TRF budesonide between 1st January 2024 and 31st July 2025 at a single renal centre in the UK, with follow-up until 31st January 2026. Outcomes were changes in urine protein-to-creatinine ratio (UPCR) and eGFR from baseline to 3, 6, and 9 months and to the latest follow-up, assessed within patients using the Wilcoxon signed rank test. Intention-to-treat (ITT; all 33 patients commencing therapy) and per-protocol (PP; ≥6 months of therapy and not switched directly from modified-release budesonide) analyses were performed. Pre- and post-treatment eGFR slopes were compared using linear mixed-effects models, and a historical comparator cohort matched on baseline UPCR was drawn from the Salford Kidney Study; both are reported as exploratory.Results
Thirty-three patients commenced TRF budesonide, of whom 23 met PP criteria. Median age was 44 (IQR 37-60) years, baseline UPCR 212 (133-289) mg/mmol, and eGFR 48 (30-61) mL/min/1.73 m2. Renin-angiotensin system (RAS) inhibitor and sodium-glucose cotransporter-2 (SGLT2) inhibitor use were 94% and 91%, respectively. At the latest follow-up (median 11.2 months after treatment initiation), UPCR decreased by 60% (IQR 31-71%) in the ITT cohort (p < 0.001) and 57% (IQR 26-72%) in the PP cohort (p < 0.001). eGFR was stable across the treatment period, with no significant change from baseline at 9 months or at the latest follow-up in either analysis set. Pre- to post-treatment slope comparison was confounded by initiation of SGLT2 inhibitor therapy within the pre-treatment observation window and is reported as exploratory. An adverse effect was recorded in 9 of 33 patients (27%). Seven patients (21%) discontinued treatment, 6 for non-serious adverse effects and 1 for a serious adverse event (staphylococcal septicaemia requiring hospital admission); treatment was temporarily suspended in 1 further patient.Conclusion
In a real-world IgAN cohort with near-universal RAS and SGLT2 inhibitor use, TRF budesonide was associated with substantial proteinuria reduction, additive to optimised background therapy. eGFR was stable over the treatment period. Slope-based analyses could not be interpreted, because background SGLT2 inhibitor therapy was initiated within the pre-treatment observation window in nearly every patient. Discontinuation for adverse effects was more frequent than in trials, though symptoms were generally mild; adverse event frequencies are not directly comparable given retrospective ascertainment.
Related
- Targeted-Release Budesonide in Chinese Patients with IgA Nephropathy: A Real-World Retrospective Cohort Study.
- Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study
- Mapping the complement-targeted landscape in igA nephropathy: a systematic review with structured descriptive synthesis
- Comparative efficacy and safety of targeted disease-modifying therapies in adults with primary IgA nephropathy: a systematic review and network meta-analysis
- The BAFF/APRIL system in autoimmune nephropathy: from pathogenesis to targeted biologic therapies.
BibTeX
@article{mcdonnell2026realworld,
title = {{Real-World Effectiveness of Targeted-Release Budesonide in IgA Nephropathy with Near-Universal SGLT2 Inhibitor Use.}},
author = {Thomas McDonnell and William R Marshall and Sharmilee Rengarajan and Jude Allen and Rajkumar Chinnadurai and Smeeta Sinha and Philip A Kalra},
journal = {American journal of nephrology},
year = {2026},
month = oct,
doi = {10.1159/ajn/ablag015},
url = {https://europepmc.org/article/MED/42879331},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real-World Effectiveness of Targeted-Release Budesonide in IgA Nephropathy with Near-Universal SGLT2 Inhibitor Use.
AU - Thomas McDonnell
AU - William R Marshall
AU - Sharmilee Rengarajan
AU - Jude Allen
AU - Rajkumar Chinnadurai
AU - Smeeta Sinha
AU - Philip A Kalra
PY - 2026
DA - 2026/10/15
JO - American journal of nephrology
DO - 10.1159/ajn/ablag015
UR - https://europepmc.org/article/MED/42879331
AB - Introduction IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of end-stage kidney disease. Targeted-release formulation (TRF) budesonide demonstrated significant reductions in proteinuria and attenuation of estimated glomerular filtration rate (eGFR) decline in the randomised NefIgArd trial. However, real-world effectiveness and tolerability in routine clinical practice remain less well characterised. We report real-world outcomes following initiation of TRF budesonide in a tertiary renal centre.Methods We conducted a retrospective cohort study of all patients with biopsy-proven IgAN initiated on TRF budesonide between 1st January 2024 and 31st July 2025 at a single renal centre in the UK, with follow-up until 31st January 2026. Outcomes were changes in urine protein-to-creatinine ratio (UPCR) and eGFR from baseline to 3, 6, and 9 months and to the latest follow-up, assessed within patients using the Wilcoxon signed rank test. Intention-to-treat (ITT; all 33 patients commencing therapy) and per-protocol (PP; ≥6 months of therapy and not switched directly from modified-release budesonide) analyses were performed. Pre- and post-treatment eGFR slopes were compared using linear mixed-effects models, and a historical comparator cohort matched on baseline UPCR was drawn from the Salford Kidney Study; both are reported as exploratory.Results Thirty-three patients commenced TRF budesonide, of whom 23 met PP criteria. Median age was 44 (IQR 37-60) years, baseline UPCR 212 (133-289) mg/mmol, and eGFR 48 (30-61) mL/min/1.73 m2. Renin-angiotensin system (RAS) inhibitor and sodium-glucose cotransporter-2 (SGLT2) inhibitor use were 94% and 91%, respectively. At the latest follow-up (median 11.2 months after treatment initiation), UPCR decreased by 60% (IQR 31-71%) in the ITT cohort (p < 0.001) and 57% (IQR 26-72%) in the PP cohort (p < 0.001). eGFR was stable across the treatment period, with no significant change from baseline at 9 months or at the latest follow-up in either analysis set. Pre- to post-treatment slope comparison was confounded by initiation of SGLT2 inhibitor therapy within the pre-treatment observation window and is reported as exploratory. An adverse effect was recorded in 9 of 33 patients (27%). Seven patients (21%) discontinued treatment, 6 for non-serious adverse effects and 1 for a serious adverse event (staphylococcal septicaemia requiring hospital admission); treatment was temporarily suspended in 1 further patient.Conclusion In a real-world IgAN cohort with near-universal RAS and SGLT2 inhibitor use, TRF budesonide was associated with substantial proteinuria reduction, additive to optimised background therapy. eGFR was stable over the treatment period. Slope-based analyses could not be interpreted, because background SGLT2 inhibitor therapy was initiated within the pre-treatment observation window in nearly every patient. Discontinuation for adverse effects was more frequent than in trials, though symptoms were generally mild; adverse event frequencies are not directly comparable given retrospective ascertainment.
SN - 0250-8095
SN - 1421-9670
ER -